Ocular Therapeutix (OCUL) Reports Q4 Revenues Below Estimates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Ocular Therapeutix (OCUL) PT Raised to $22 at Cantor Fitzgerald; 'Preparing for a Momentous 2018'
March 8, 2018 10:42 AM ESTCantor Fitzgerald analyst Elemer Piros raised his price target on Ocular Therapeutix (NASDAQ: OCUL) to $22.00 (from $21.00) while maintaining a Overweight rating, saying the company is preparing for a 'momentous 2018'.
Piros commented, "Ocular hosted a conference call to review its quarterly progress and... More
